Cambridge Investment Research Advisors Inc. Increases Stake in DaVita Inc. (NYSE:DVA)

Cambridge Investment Research Advisors Inc. raised its stake in shares of DaVita Inc. (NYSE:DVA) by 3.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,945 shares of the company’s stock after buying an additional 101 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in DaVita were worth $342,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. New York State Common Retirement Fund grew its holdings in DaVita by 0.8% during the 3rd quarter. New York State Common Retirement Fund now owns 85,551 shares of the company’s stock valued at $9,946,000 after buying an additional 712 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of DaVita by 96.6% in the third quarter. Nordea Investment Management AB now owns 1,038,086 shares of the company’s stock valued at $125,682,000 after purchasing an additional 510,106 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of DaVita by 2.5% in the third quarter. Commonwealth Equity Services LLC now owns 22,566 shares of the company’s stock valued at $2,623,000 after purchasing an additional 556 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in shares of DaVita by 13.1% in the third quarter. Vontobel Holding Ltd. now owns 2,081 shares of the company’s stock valued at $241,000 after purchasing an additional 241 shares in the last quarter. Finally, WINTON GROUP Ltd grew its holdings in shares of DaVita by 8.4% in the third quarter. WINTON GROUP Ltd now owns 6,425 shares of the company’s stock valued at $747,000 after purchasing an additional 497 shares in the last quarter. 86.54% of the stock is owned by institutional investors and hedge funds.

NYSE:DVA opened at $116.32 on Friday. DaVita Inc. has a twelve month low of $94.38 and a twelve month high of $136.48. The company has a market cap of $11.85 billion, a price-to-earnings ratio of 13.54, a price-to-earnings-growth ratio of 1.15 and a beta of 1.24. The stock has a fifty day simple moving average of $106.73 and a 200-day simple moving average of $116.28. The company has a current ratio of 1.62, a quick ratio of 1.58 and a debt-to-equity ratio of 6.60.

DaVita (NYSE:DVA) last released its earnings results on Thursday, October 28th. The company reported $2.36 earnings per share for the quarter, topping the consensus estimate of $2.26 by $0.10. DaVita had a return on equity of 67.99% and a net margin of 8.33%. The business had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.91 billion. During the same period last year, the company earned $1.80 earnings per share. The business’s revenue for the quarter was up .5% compared to the same quarter last year. As a group, equities research analysts predict that DaVita Inc. will post 8.89 EPS for the current fiscal year.

DVA has been the subject of a number of recent research reports. Zacks Investment Research raised shares of DaVita from a “sell” rating to a “hold” rating and set a $121.00 target price for the company in a report on Tuesday, January 4th. Royal Bank of Canada lowered their price target on DaVita from $113.00 to $111.00 and set a “sector perform” rating for the company in a research report on Friday, October 29th. Truist raised their price target on DaVita from $114.00 to $125.00 and gave the stock a “hold” rating in a research report on Wednesday, January 5th. Truist Securities raised their price target on DaVita from $114.00 to $125.00 and gave the stock a “hold” rating in a research report on Wednesday, January 5th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on DaVita from $164.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, November 17th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $130.13.

In other news, Director Pamela M. Arway sold 446 shares of DaVita stock in a transaction on Tuesday, November 23rd. The stock was sold at an average price of $102.86, for a total transaction of $45,875.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.00% of the stock is currently owned by company insiders.

DaVita Profile

DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.

Featured Story: How to calculate the annual rate of depreciation

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA).

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.